<unk>  is a cardioselective beta-1 blocker which also considered a partial agonist due to its intrinsic sympathomimetic<unk> tivity (ISA). This means it provides low-grade beta stimulation at rest but<unk> ting as typical beta-blockers when sympathetic<unk> tivity is high. Among other drugs in the beta-blocker class,<unk>  will provide beta-blockade effects to a lesser extent. Due to its cardioselectivity,<unk>  is more suitable than non-cardioselective beta-blockers, in a patient with asthma or chronic obstructive pulmonary disease (COPD) who needs treatment with a beta-blocker. This cardio-specificity will minimize the anti-hypertensive effects as seen with non-specific beta blockers such as Propanalol and Nadolol. (For these reasons, it may be a beta-blocker of choice in inclusion in Polypill strategies). In doses lower than 800 mg daily its constricting effects on the bronchial system and smooth muscle vessels are only 10% to 30% of those observed under propranolol treatment, but there is experimental evidence that the cardioselective properties diminish at doses of 800 mg/day or more. The drug has lipophilic properties and therefore crosses the blood–brain barrier.<unk>  has no negative impact on serum lipids (cholesterol and triglycerides). No HDL decrease has been observed. In this regard, it is unlike many other beta-blockers which have this unfavourable property. The drug works in hypertensive patients with high, normal, or low renin plasma concentrations, although<unk>  may be more efficient in patients with high or normal renin plasma concentrations. In clinically relevant concentrations, a membrane-stabilizing effect does not appear to play an important role.
Acebutolol
Hydrastine
Tolbutamide
Prazosin
Phenylephrine
Telmisartan
Sildenafil
Metergoline